Yew Bio-Pharm Group Inc. (YEWB) Releases Earnings Results

Yew Bio-Pharm Group Inc. (OTCMKTS:YEWB) issued its quarterly earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Yew Bio-Pharm Group had a net margin of 20.09% and a return on equity of 23.77%.

Shares of Yew Bio-Pharm Group (OTCMKTS:YEWB) remained flat at $$0.22 on Tuesday. Yew Bio-Pharm Group has a fifty-two week low of $0.15 and a fifty-two week high of $0.47. The stock has a market capitalization of $11.41, a PE ratio of 1.22 and a beta of -1.41.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/yew-bio-pharm-group-inc-yewb-releases-earnings-results.html.

About Yew Bio-Pharm Group

Yew Bio-Pharm Group, Inc is a grower and seller of yew trees and manufacturer of products made from yew trees in China. The Company operates through five segments: traditional Chinese medicine (TCM) raw materials, which is engaged in the production and sale of raw materials used for medicinal application in the pharmaceutical industry; yew trees, which is engaged in the cultivation and sale of yew seedlings, yew trees and potted yew trees; handicrafts, which is engaged in the manufacture and sale of furniture and handicrafts made of yew timber; wood ear mushroom, which includes the sale of wood ear mushroom, and others, which includes the sale of yew candles and pine needle extracts.

Receive News & Ratings for Yew Bio-Pharm Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yew Bio-Pharm Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply